Article: Cytokine PharmaSciences Licenses Anti-MIF Technology To Baxter Healthcare Corporation.

Article: Anti-MIF technology licensed to large pharmaceutical company.(Cytokine PharmaSciences Inc. and Baxter Healthcare Corp. sign licensing agreement)(Brief Article)
Cancer Weekly;  April 8, 2003 ;     230 words ......8 - (NewsRx.com & NewsRx.net) -- Cytokine PharmaSciences, Inc., has signed an exclusive license with Baxter Healthcare Corporation...Denny Willson, president and CEO of Cytokine PharmaSciences. Baxter is a top-tier player in...

Article: Cytokine PharmaSciences Announces Retirement of Richard P. Storm, VP, Corporate Development and Founder.
PR Newswire;  January 7, 2005 ;     306 words ......PRUSSIA, Pa., Jan. 7 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the retirement...Willson, president and CEO of Cytokine PharmaSciences, stated: Richard is a classic...where he worked until founding Cytokine PharmaSciences in 1992. Cytokine ...

Article: Cytokine PharmaSciences, Inc. Issued Patent for MIF Gene Polymorphism Diagnostics.
PR Newswire;  May 3, 2007 ;     366 words ......PRUSSIA, Pa., May 3 /PRNewswire/ -- Cytokine PharmaSciences, Inc. (CPSI) today announced issuance...Willson, President and CEO of Cytokine PharmaSciences, stated: MIF is increasingly recognized...effective anti-MIF therapeutics. Cytokine PharmaSciences is a biopharmaceutical ...

Article: David E. Robinson Joins Board of Cytokine PharmaSciences.
PR Newswire;  January 12, 2004 ;     338 words ......Pa., Jan. 12 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the election...Willson, president and CEO of Cytokine PharmaSciences. He will help take us to the next...integrated pharmaceutical business. Cytokine PharmaSciences is a biopharmaceutical company...

Article: Genmab Licenses MIF Receptor Target From Cytokine PharmaSciences.
PR Newswire;  November 20, 2006 ;     643 words ......PRNewswire-FirstCall/ -- Genmab A/S and Cytokine PharmaSciences, Inc. announced today that Genmab...to the MIF receptor target from Cytokine PharmaSciences. Genmab intends to develop therapeutic...Willson, president and CEO of Cytokine PharmaSciences, stated: Genmab is a ...

Article: Cytokine PharmaSciences Names Vidal F. de la Cruz, Ph.D., Vice President, Business Development.
PR Newswire;  December 9, 2004 ;     215 words ......PRUSSIA, Pa., Dec. 9 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the promotion...Willson, President and CEO of Cytokine PharmaSciences. Vidal has made an important contribution...President of Business Development. Cytokine PharmaSciences is a biopharmaceutical ...

Article: Obstetric product licensed out for marketing.(Cytokine PharmaSciences Inc., Integrity Pharmaceutical Corp. sign marketing agreement for cervical ripening product)(Brief Article)
Women's Health Weekly;  May 1, 2003 ;     197 words ...2003 MAY 1 - (NewsRx.com & NewsRx.net) -- Cytokine PharmaSciences, Inc., (CPSI) has signed an exclusive license with Integrity Pharmaceutical Corporation for U.S. rights to market CPSI's second-generation cervical ripening product. Cervical...

Article: Cytokine PharmaSciences Inc.-Company Report.
M2 Presswire;  February 4, 2009 ;     249 words ......companiesandmarkets.com: Cytokine PharmaSciences Inc.-Company Report...adds new report: Cytokine PharmaSciences Inc.-Company Report...

Article: Cytokine PharmaSciences Licenses Obstetric Product to Integrity Pharmaceutical Corporation.
PR Newswire;  April 3, 2003 ;     433 words ......Pa., April 3 /PRNewswire/ -- Cytokine PharmaSciences, Inc. (CPSI) has signed an exclusive license with Integrity Pharmaceutical...Willson President & CEO Cytokine PharmaSciences, Inc. (610) 687-1776 ext. 211...Willson, President & CEO of Cytokine PharmaSciences, ...

Article: Genmab licenses MIF from Cytokine PharmaSciences.(macrophage migration inhibitory factor)(Brief article)
Pharma Marketletter;  November 27, 2006 ;     67 words ......biotechnology company Genmab AS says that it has licensed rights to a macrophage migration inhibitory factor (MIF) receptor from Cytokine PharmaSciences of the USA. MIF is a pro-inflammatory cytokine that is known to activate T cells and macrophages. Genmab said that it...

Article: University Technologies International (UTI), the University of Calgary's technology transfer, commercialization and incubation center, and Materia Inc., Pasadena, CA, have announced the signing of an exclusive license agreement for olefin metathesis catalysts developed by Dr. Warren Piers.(COMPANY NEWS)
Adhesives & Sealants Industry;  October 1, 2008 ;     105 words ......have announced the signing of an exclusive license agreement for olefin metathesis catalysts...developed by Dr. Warren Piers. This exclusive license is an expansion of the 2004 agreement...Materia to expand its agreement to an exclusive license that allows it the right to sell...

Article: Solterra Inks Exclusive License with Rice University
Wireless News;  October 15, 2008 ;     355 words ...Solterra Inks Exclusive License with Rice University WIRELESS NEWS-October 15, 2008-Solterra Inks Exclusive License with Rice University (C)2008...Technologies has concluded the worldwide exclusive license with the William Marsh Rice University...

Article: Telwares Inks Exclusive License Pact with CombineNet
Wireless News;  December 13, 2008 ;     352 words ...Telwares Inks Exclusive License Pact with CombineNet WIRELESS...NEWS-December 13, 2008-Telwares Inks Exclusive License Pact with CombineNet (C)2008...CombineNet have announced an exclusive license arrangement under which Telwares...

Article: GRAPE COMMISSION GETS EXCLUSIVE LICENSE.(Brief Article)
The Food Institute Report;  May 7, 2001 ;     59 words ...GRAPE COMMISSION GETS EXCLUSIVE LICENSE: USDA intends to grant the Fresno- based California Table Grape Commission an exclusive license to the table grape variety Princess ' in selected countries outside the U.S. where breeder's rights are available...